Obalon Therapeutics (OBLN) Given Hold Rating at Northland Securities

Northland Securities restated their hold rating on shares of Obalon Therapeutics (NASDAQ:OBLN) in a research report released on Wednesday. The firm currently has a $4.00 price target on the stock.

Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Obalon Therapeutics from a hold rating to a buy rating and set a $5.00 price objective for the company in a research report on Wednesday, February 14th. BTIG Research reiterated a buy rating and set a $15.00 price objective on shares of Obalon Therapeutics in a research report on Thursday, November 16th. Canaccord Genuity reiterated a buy rating and set a $11.00 price objective (down from $15.00) on shares of Obalon Therapeutics in a research report on Monday, January 22nd. They noted that the move was a valuation call. Finally, UBS Group decreased their price objective on shares of Obalon Therapeutics from $20.00 to $16.00 and set a buy rating for the company in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $10.20.

Shares of Obalon Therapeutics (NASDAQ OBLN) opened at $4.20 on Wednesday. Obalon Therapeutics has a 12-month low of $3.40 and a 12-month high of $13.18. The company has a debt-to-equity ratio of 0.21, a quick ratio of 8.65 and a current ratio of 8.78. The firm has a market cap of $95.87 and a price-to-earnings ratio of -2.18.

Large investors have recently bought and sold shares of the business. Granite Investment Partners LLC acquired a new stake in Obalon Therapeutics in the third quarter worth $1,036,000. Northern Trust Corp grew its holdings in Obalon Therapeutics by 109.8% in the second quarter. Northern Trust Corp now owns 92,237 shares of the company’s stock worth $914,000 after purchasing an additional 48,268 shares during the period. Emerald Mutual Fund Advisers Trust grew its holdings in Obalon Therapeutics by 89.4% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 63,171 shares of the company’s stock worth $602,000 after purchasing an additional 29,818 shares during the period. C WorldWide Group Holding A S grew its holdings in Obalon Therapeutics by 13.7% in the third quarter. C WorldWide Group Holding A S now owns 276,211 shares of the company’s stock worth $2,632,000 after purchasing an additional 33,318 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Obalon Therapeutics by 33.9% in the second quarter. Bank of New York Mellon Corp now owns 21,135 shares of the company’s stock worth $210,000 after purchasing an additional 5,353 shares during the period. Institutional investors and hedge funds own 44.22% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Obalon Therapeutics (OBLN) Given Hold Rating at Northland Securities” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/22/obalon-therapeutics-obln-given-hold-rating-at-northland-securities.html.

About Obalon Therapeutics

Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.

Receive News & Ratings for Obalon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply